Clinicians > Further Indications >
Ocular Melanoma


Published Data in Metastatic Ocular Melanoma

SIR-Spheres® Y-90 resin microspheres have shown benefits in the first-line treatment of treatment-refractory liver metastases from melanoma (predominantly from ocular or uveal primary tumours).

In a mixed population of patients with unresectable cutaneous or ocular metastatic melanoma that was refractory to systemic therapy, SIR-Spheres Y-90 resin microspheres were associated with longer survival from diagnosis of the metastatic melanoma than best supportive care (19.9 months vs. 4.8 months).1 Other non-comparative studies of SIRT with SIR-Spheres Y-90 resin microspheres for metastatic melanoma have demonstrated similar or longer survival from diagnosis (19.0–23.9 months).2,3

SIR-Spheres Y-90 resin microspheres are generally well tolerated in this clinical setting.

Summary of SIR-Spheres Y-90 resin microspheres in mOM

1 Xing M. et al. Am J Clin Oncol 2014 Aug 1; ePub doi: 10.1097/COC.0000000000000109.
2 Klingenstein A. et al. Cardiovasc Intervent Radiol 2013; 36: 158-165.
3 Eldredge-Hindy H. et al. Am J Clin Oncol 2016; 39: 189-195.

Ongoing mOM Studies

Ongoing studies of SIR-Spheres® Y-90 resin microspheres in the treatment of mOM:

Title Setting Sponsor Study ID Treatment Arm(s) N Location
SIRUM (TJU)
SIR-Spheres microspheres treatment of uveal melanoma metastasised to liver		 Uveal melanoma Investigator-Initiated Research Study NCT01473004 SIR-Spheres Y-90 resin microspheres 48 USA
SIRTAC
SIR-Spheres microspheres vs. TACE treatment of uveal melanoma metastasised to liver		 Uveal melanoma Investigator-Initiated Research Study NCT02936388 SIR-Spheres Y-90 resin microspheres vs. TACE (cisplatin+embocept) 108 Germany
SORASIRT
Sorafenib and radioembolisation with SIR Spheres for the treatment of metastatic ocular melanoma		 Uveal melanoma Investigator-Initiated Research Study NCT01893099 SIR Spheres Y-90 resin microspheres > sorafenib or sorafenib > SIR Spheres Y-90 resin microspheres 24 Switzerland

 



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage